For the quarter ending 2025-09-30, MRVI had -$26,333K decrease in cash & cash equivalents over the period. -$18,076K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -45,057 | -122,690 |
| Change in estimated fair value of contingent consideration | - | -140 |
| Depreciation | -5,975 | -11,650 |
| Amortization of intangible assets | 7,209 | 14,230 |
| Amortization of operating lease right-of-use assets | 2,259 | 4,416 |
| Amortization of deferred financing costs | 399 | 852 |
| Stock-based compensation expense | 9,056 | 17,192 |
| Change in estimated fair value of contingent consideration | 0 | - |
| Goodwill impairment | 0 | -42,884 |
| Acquisition related tax adjustment | 0 | -4,082 |
| Change in fair value of derivative instruments | 0 | 0 |
| Other | -334 | -957 |
| Accounts receivable | -5,116 | -10,661 |
| Inventory | -1,350 | -3,557 |
| Prepaid expenses and other current and noncurrent assets | -1,066 | 621 |
| Deferred revenue | - | -735 |
| Accounts payable | -2,906 | 1,074 |
| Accrued expenses and other current liabilities | 1,514 | 7,374 |
| Other long-term liabilities | -2,060 | -14,678 |
| Net cash (used in) provided by operating activities | -15,150 | -19,655 |
| Cash paid for acquisitions of a business, net of cash acquired | 0 | 18,990 |
| Purchases of property and equipment | 2,926 | 8,109 |
| Proceeds from government assistance allocated to property and equipment | 0 | 734 |
| Purchase of technology | 0 | - |
| Net cash used in investing activities | -2,926 | -26,365 |
| Distributions for tax liabilities to non-controlling interest holder | 0 | 0 |
| Principal repayments of long-term debt | 1,360 | 2,720 |
| Payments of finance lease liabilities | 200 | 370 |
| Proceeds from interest rate cap agreement | 0 | 1,375 |
| Payments of acquisition related contingent consideration and consideration holdback | 6,800 | - |
| Taxes paid for shares withheld under employee equity plans, net of proceeds from issuance of class a common stock | 111 | -4,719 |
| Net cash (used in) provided by financing activities | -8,249 | -6,434 |
| Effects of exchange rate changes on cash and cash equivalents | -8 | -38 |
| Net (decrease) increase in cash and cash equivalents | -26,333 | -52,492 |
| Cash and cash equivalents at beginning of period | 322,399 | - |
| Cash and cash equivalents at end of period | 243,574 | - |
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)